Market Overview

UPDATE: Wedbush Lowers Illumina's PT


According to a research report published this morning, Wedbush has decreased Illumina's (NASDAQ: ILMN) PT from $65 to $52.

In the report, Wedbush commented, "With Roche out of the picture, we have reassessed our valuation framework. We are lowering our price target from $65 to $52, which assumes a 2012E EV/sales multiple of 5.5x versus our prior 7.5x multiple, which was based on the price Roche paid for Ventana in 2008. Additionally our $52 price target assumes a 2012E FCF yield of 4.6%, in line with the current diagnostics peer group median."

Wedbush maintains its Outperform rating on Illumina, which closed yesterday at $43.90.

Posted-In: WedbushAnalyst Color Price Target Analyst Ratings


Related Articles (ILMN)

View Comments and Join the Discussion!

Latest Ratings

RPAYCantor FitzgeraldMaintains18.0
CMSCredit SuisseDowngrades
PBCTStephens & Co.Maintains15.5
TTECCowen & Co.Initiates Coverage On50.0
View the Latest Analytics Ratings
Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Premarket Activity
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Daily Analyst Rating
A summary of each day’s top rating changes from sell-side analysts on the street.
Fintech Focus
A daily collection of all things fintech, interesting developments and market updates.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at